Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Analysis From Nishith Desai Associates: Learning And Unlearning From Section 3(d) Of The Indian Patents Act (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

By Milind Antani and Gowree Gokhale, Nishith Desai Associates, Mumbai, Indi

You may also be interested in...



Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings

Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations

Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings

Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations

India's Expert Group Says Denying Patents To Incremental Innovations Will Not Be TRIPS-Compliant; Evergreening To Be Scrupulously Prevented

MUMBAI - Putting to rest wide speculation about applicability of the controversial Section 3 (d) of the Indian Patents Act, which deals with the treatment of incremental innovations, the Mashelkar Committee report - set up to dwell on Indian patent law issues - has recommended that incremental innovations should be encouraged

Related Content

UsernamePublicRestriction

Register

SC072042

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel